EP2281579A1
(en)
*
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
CN104531812A
(zh)
|
2010-10-01 |
2015-04-22 |
现代治疗公司 |
设计核酸及其使用方法
|
WO2012135805A2
(en)
|
2011-03-31 |
2012-10-04 |
modeRNA Therapeutics |
Delivery and formulation of engineered nucleic acids
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
RU2707251C2
(ru)
|
2011-10-03 |
2019-11-25 |
Модерна Терапьютикс, Инк. |
Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
|
EP2791364A4
(en)
*
|
2011-12-14 |
2015-11-11 |
Moderna Therapeutics Inc |
METHODS OF RESPONSE TO A BIOLOGICAL THREAT
|
KR20140102759A
(ko)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
EP2833892A4
(en)
|
2012-04-02 |
2016-07-20 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS AND PEPTIDES ASSOCIATED WITH ONCOLOGY
|
US9512456B2
(en)
|
2012-08-14 |
2016-12-06 |
Modernatx, Inc. |
Enzymes and polymerases for the synthesis of RNA
|
US20150307542A1
(en)
|
2012-10-03 |
2015-10-29 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
AU2013343864B2
(en)
*
|
2012-11-09 |
2019-04-04 |
BioNTech SE |
Method for cellular RNA expression
|
JP6144355B2
(ja)
|
2012-11-26 |
2017-06-07 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
化学修飾mRNA
|
WO2014159813A1
(en)
|
2013-03-13 |
2014-10-02 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
SG10201801428RA
(en)
*
|
2013-08-21 |
2018-03-28 |
Curevac Ag |
Method for increasing expression of rna-encoded proteins
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
US10323076B2
(en)
|
2013-10-03 |
2019-06-18 |
Modernatx, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
EP3090060B1
(en)
|
2013-12-30 |
2019-02-20 |
CureVac AG |
Methods for rna analysis
|
SG11201604198YA
(en)
|
2013-12-30 |
2016-07-28 |
Curevac Ag |
Methods for rna analysis
|
CA2939950C
(en)
|
2014-03-09 |
2023-08-22 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
|
BR112016024644A2
(pt)
|
2014-04-23 |
2017-10-10 |
Modernatx Inc |
vacinas de ácido nucleico
|
ES2727776T3
(es)
|
2014-06-10 |
2019-10-18 |
Curevac Ag |
Método para mejorar la producción de ARN
|
CA2955250A1
(en)
|
2014-07-16 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
WO2016077125A1
(en)
|
2014-11-10 |
2016-05-19 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules containing reduced uracil content and uses thereof
|
EP3233880A1
(en)
|
2014-12-16 |
2017-10-25 |
Novartis AG |
End capped nucleic acid molecules
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
EP3261605B2
(en)
|
2015-02-26 |
2022-04-20 |
SiO2 Medical Products, Inc. |
Cycloolefin polymer container with a scratch resistant and anti-static coating
|
MX2017013321A
(es)
|
2015-04-22 |
2018-07-06 |
Curevac Ag |
Composicion que contiene arn para tratamiento de enfermedades tumorales.
|
JP6851319B2
(ja)
|
2015-04-27 |
2021-03-31 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ヒト疾患のCRISPR/Cas9媒介性の修正のためのデュアルAAVベクター系
|
CN107873055B
(zh)
|
2015-05-29 |
2021-09-17 |
库瑞瓦格房地产有限公司 |
包括至少一个切向流过滤步骤的产生和纯化rna的方法
|
WO2017001058A1
(en)
|
2015-07-01 |
2017-01-05 |
Curevac Ag |
Method for analysis of an rna molecule
|
EP3325018A4
(en)
|
2015-07-22 |
2019-04-24 |
Duke University |
HIGH EFFICIENCY SCREENING OF REGULATORY ELEMENT FUNCTION USING EPIGENOUS EDITING TECHNOLOGIES
|
CA2996001A1
(en)
|
2015-08-25 |
2017-03-02 |
Duke University |
Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
|
JP2018527003A
(ja)
|
2015-09-17 |
2018-09-20 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
安定化尾部領域を含むポリヌクレオチド
|
HRP20220156T1
(hr)
|
2015-09-17 |
2022-04-15 |
Modernatx, Inc. |
Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
|
AU2016336344A1
(en)
|
2015-10-05 |
2018-04-19 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
US11970710B2
(en)
|
2015-10-13 |
2024-04-30 |
Duke University |
Genome engineering with Type I CRISPR systems in eukaryotic cells
|
CA3001014A1
(en)
*
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs and methods of mrna capping
|
US11866754B2
(en)
|
2015-10-16 |
2024-01-09 |
Modernatx, Inc. |
Trinucleotide mRNA cap analogs
|
ES2914225T3
(es)
|
2015-10-16 |
2022-06-08 |
Modernatx Inc |
Análogos de cap de ARNm con enlace de fosfato modificado
|
DK3394030T3
(da)
|
2015-12-22 |
2022-03-28 |
Modernatx Inc |
Forbindelser og sammensætninger til intracellulær afgivelse af midler
|
US11248223B2
(en)
|
2015-12-23 |
2022-02-15 |
Curevac Ag |
Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
EP3405579A1
(en)
|
2016-01-22 |
2018-11-28 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
PL415967A1
(pl)
*
|
2016-01-29 |
2017-07-31 |
Univ Warszawski |
5'-tiofosforanowe analogi końca 5' mRNA (kapu), sposób ich otrzymywania i zastosowanie
|
US20190049414A1
(en)
|
2016-02-15 |
2019-02-14 |
Curevac Ag |
Method for analyzing by-products of rna in vitro transcription
|
WO2017149139A1
(en)
|
2016-03-03 |
2017-09-08 |
Curevac Ag |
Rna analysis by total hydrolysis
|
WO2017162266A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Rna replicon for versatile and efficient gene expression
|
WO2017162265A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Trans-replicating rna
|
US20190167811A1
(en)
|
2016-04-13 |
2019-06-06 |
Modernatx, Inc. |
Lipid compositions and their uses for intratumoral polynucleotide delivery
|
EP4233898A3
(en)
|
2016-05-04 |
2023-11-01 |
CureVac SE |
Influenza mrna vaccines
|
EP3452493A1
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Nucleic acid molecules and uses thereof
|
SI3458083T1
(sl)
|
2016-05-18 |
2023-03-31 |
Modernatx, Inc. |
Polinukleotidi, ki kodirajo interlevkin-12 (IL12) in njihova uporaba
|
ES2901215T3
(es)
|
2016-05-27 |
2022-03-21 |
Aadigen Llc |
Péptidos y nanopartículas para la liberación intracelular de moléculas de edición del genoma
|
US20200069599A1
(en)
|
2016-06-14 |
2020-03-05 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
WO2018033254A2
(en)
|
2016-08-19 |
2018-02-22 |
Curevac Ag |
Rna for cancer therapy
|
EP3532094A1
(en)
|
2016-10-26 |
2019-09-04 |
CureVac AG |
Lipid nanoparticle mrna vaccines
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
WO2018115507A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Henipavirus vaccine
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
EP3585895A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Compositions and methods for gene editing
|
AU2018234828A1
(en)
|
2017-03-15 |
2019-09-19 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
KR20190132405A
(ko)
|
2017-03-15 |
2019-11-27 |
모더나티엑스, 인크. |
치료제의 세포내 전달을 위한 화합물 및 조성물
|
US20210198200A1
(en)
|
2017-06-14 |
2021-07-01 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
US20200131498A1
(en)
|
2017-06-14 |
2020-04-30 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
SG11201911430PA
(en)
|
2017-07-04 |
2020-01-30 |
Curevac Ag |
Novel nucleic acid molecules
|
WO2019036638A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
METHODS FOR PREPARING MODIFIED RNA
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
EP3681901B1
(en)
|
2017-09-13 |
2024-03-27 |
BioNTech SE |
Method of enhancing rna expression in a cell
|
US20200283497A1
(en)
|
2017-09-13 |
2020-09-10 |
Biontech Cell & Gene Therapies Gmbh |
Rna replicon for expressing at cell receptor or an artificial t cell receptor
|
US20200277627A1
(en)
|
2017-09-13 |
2020-09-03 |
Biontech Rna Pharmaceuticals Gmbh |
Rna replicon for reprogramming somatic cells
|
EP3707271A1
(en)
|
2017-11-08 |
2020-09-16 |
CureVac AG |
Rna sequence adaptation
|
US11931406B2
(en)
|
2017-12-13 |
2024-03-19 |
CureVac SE |
Flavivirus vaccine
|
SG11202005760PA
(en)
|
2017-12-21 |
2020-07-29 |
Curevac Ag |
Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
|
JP7416705B2
(ja)
*
|
2018-03-15 |
2024-01-17 |
バイオエヌテック エスエー |
5’キャップトリヌクレオチドまたはより高級のオリゴヌクレオチド化合物、ならびにrnaの安定化、タンパク質の発現および治療法におけるそれらの使用
|
US20210361761A1
(en)
|
2018-04-05 |
2021-11-25 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
SG11202008225PA
(en)
|
2018-04-17 |
2020-11-27 |
Curevac Ag |
Novel rsv rna molecules and compositions for vaccination
|
WO2020002525A1
(en)
|
2018-06-27 |
2020-01-02 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
WO2020061367A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
US20220040281A1
(en)
|
2018-12-21 |
2022-02-10 |
Curevac Ag |
Rna for malaria vaccines
|
EP3899034A1
(en)
|
2018-12-21 |
2021-10-27 |
CureVac AG |
Methods for rna analysis
|
TW202043272A
(zh)
|
2019-01-14 |
2020-12-01 |
美商建南德克公司 |
使用pd-1軸結合拮抗劑及rna疫苗治療癌症之方法
|
AU2020214843A1
(en)
|
2019-01-31 |
2021-08-19 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
JP2022523117A
(ja)
|
2019-01-31 |
2022-04-21 |
モデルナティエックス インコーポレイテッド |
ボルテックスミキサならびにその関連する方法、システム、及び装置
|
WO2020161342A1
(en)
|
2019-02-08 |
2020-08-13 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
WO2020254535A1
(en)
|
2019-06-18 |
2020-12-24 |
Curevac Ag |
Rotavirus mrna vaccine
|
BR112022001947A2
(pt)
|
2019-08-14 |
2022-09-20 |
Curevac Ag |
Combinações e composições de rna com propriedades imunoestimuladoras reduzidas
|
MX2022007680A
(es)
|
2019-12-20 |
2022-09-26 |
Curevac Ag |
Nanoparticulas lipidicas para administracion de acidos nucleicos.
|
MX2022009391A
(es)
|
2020-01-31 |
2022-09-26 |
Genentech Inc |
Metodos para inducir linfocitos t especificos para neoepitopo con un antagonista de union al eje de pd-1 y una vacuna de arn.
|
CN116113430A
(zh)
|
2020-02-04 |
2023-05-12 |
奎尔法克股份有限公司 |
冠状病毒疫苗
|
US11576966B2
(en)
|
2020-02-04 |
2023-02-14 |
CureVac SE |
Coronavirus vaccine
|
EP4103228A1
(en)
|
2020-02-13 |
2022-12-21 |
Institut Pasteur |
Nucleic acid vaccine against the sars-cov-2 coronavirus
|
MX2022012630A
(es)
|
2020-04-09 |
2022-11-07 |
Suzhou Abogen Biosciences Co Ltd |
Composicion de nanoparticulas lipidicas.
|
EP4132576A1
(en)
|
2020-04-09 |
2023-02-15 |
Suzhou Abogen Biosciences Co., Ltd. |
Nucleic acid vaccines for coronavirus
|
KR20230015351A
(ko)
|
2020-04-22 |
2023-01-31 |
화이자 인코포레이티드 |
코로나바이러스 백신
|
EP3901261A1
(en)
|
2020-04-22 |
2021-10-27 |
BioNTech RNA Pharmaceuticals GmbH |
Coronavirus vaccine
|
GB2597436A
(en)
*
|
2020-05-12 |
2022-02-02 |
Univ Cranfield |
A method and apparatus for RNA synthesis
|
CN116322758A
(zh)
|
2020-05-29 |
2023-06-23 |
库尔维科欧洲股份公司 |
基于核酸的组合疫苗
|
JP2023527910A
(ja)
|
2020-06-04 |
2023-06-30 |
バイオエヌテック エスエー |
多用途かつ効率的な遺伝子発現のためのrnaレプリコン
|
WO2022002040A1
(en)
|
2020-06-30 |
2022-01-06 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
AU2021306613A1
(en)
|
2020-07-07 |
2023-02-02 |
BioNTech SE |
Therapeutic RNA for HPV-positive cancer
|
JP2023534283A
(ja)
|
2020-07-17 |
2023-08-08 |
ジェネンテック, インコーポレイテッド |
ペプチドの結合、提示及び免疫原性を予測するための注意ベースのニューラルネットワーク
|
EP4172194A1
(en)
|
2020-07-31 |
2023-05-03 |
CureVac SE |
Nucleic acid encoded antibody mixtures
|
JP2023536340A
(ja)
|
2020-08-06 |
2023-08-24 |
ビオンテック・ソシエタス・エウロパエア |
コロナウイルスsタンパク質のための結合剤
|
CN114391008B
(zh)
|
2020-08-20 |
2024-05-03 |
苏州艾博生物科技有限公司 |
脂质化合物和脂质纳米颗粒组合物
|
EP4157344A2
(en)
|
2020-08-31 |
2023-04-05 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
AU2021341829A1
(en)
|
2020-09-08 |
2023-04-06 |
BioNTech SE |
Systems and methods for producing pharmaceutical compositions using peristaltic pumps and dampeners
|
TW202227478A
(zh)
|
2020-09-15 |
2022-07-16 |
德商拜恩迪克公司 |
對細胞靶向遞送的藥劑及方法
|
US20240110214A1
(en)
|
2020-12-09 |
2024-04-04 |
BioNTech SE |
Rna manufacturing
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
CA3171051A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
AU2021405281A1
(en)
|
2020-12-22 |
2023-07-06 |
CureVac SE |
Rna vaccine against sars-cov-2 variants
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
WO2022152141A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Polymer conjugated lipid compounds and lipid nanoparticle compositions
|
WO2022152109A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
WO2022162027A2
(en)
|
2021-01-27 |
2022-08-04 |
Curevac Ag |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
CA3212653A1
(en)
|
2021-03-26 |
2022-09-29 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
CA3171429A1
(en)
|
2021-03-31 |
2022-09-30 |
Alexander SCHWENGER |
Syringes containing pharmaceutical compositions comprising rna
|
CN117750974A
(zh)
|
2021-04-20 |
2024-03-22 |
生物技术欧洲股份公司 |
病毒疫苗
|
JP2024518335A
(ja)
|
2021-04-26 |
2024-05-01 |
アンスティチュ パスツール |
SARS-CoV-2に対するヒト中和モノクローナル抗体、及びそれらの使用
|
WO2022233880A1
(en)
|
2021-05-03 |
2022-11-10 |
Curevac Ag |
Improved nucleic acid sequence for cell type specific expression
|
EP4334943A1
(en)
|
2021-05-04 |
2024-03-13 |
BioNTech SE |
Technologies for early detection of variants of interest
|
EP4204390A1
(en)
|
2021-05-24 |
2023-07-05 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
CA3221330A1
(en)
|
2021-06-08 |
2022-12-15 |
Biontech Cell & Gene Therapies Gmbh |
Agents and methods for activation and targeting of immune effector cells
|
EP4370551A1
(en)
|
2021-07-15 |
2024-05-22 |
BioNTech SE |
Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancers
|
KR20240042414A
(ko)
|
2021-07-29 |
2024-04-02 |
비온테크 에스이 |
흑색종의 치료용 조성물 및 방법
|
EP4377331A2
(en)
|
2021-07-30 |
2024-06-05 |
CureVac SE |
Mrnas for treatment or prophylaxis of liver diseases
|
AU2022336209A1
(en)
|
2021-09-03 |
2024-01-18 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
AU2022336664A1
(en)
|
2021-09-03 |
2024-01-18 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
EP4204391A1
(en)
|
2021-10-08 |
2023-07-05 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
AR127312A1
(es)
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
|
CN116064598B
(zh)
|
2021-10-08 |
2024-03-12 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
WO2023061550A1
(en)
|
2021-10-11 |
2023-04-20 |
BioNTech SE |
Therapeutic rna for lung cancer
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
TW202333803A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(一)
|
CA3234214A1
(en)
|
2021-10-18 |
2023-04-27 |
BioNTech SE |
Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
|
CA3234396A1
(en)
|
2021-10-18 |
2023-04-27 |
BioNTech SE |
Modified replicable rna and related compositions and their use
|
AU2021470029A1
(en)
|
2021-10-21 |
2024-05-02 |
BioNTech SE |
Coronavirus vaccine
|
EP4286003A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
EP4285932A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide complexes and uses
|
EP4186528A1
(en)
|
2021-11-30 |
2023-05-31 |
BioNTech SE |
Oligosaccharide complexes and uses
|
WO2023067121A1
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
WO2023067125A1
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Oligosaccharide complexes and uses
|
EP4169579A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Disulfide oligosaccharide compounds and complexes
|
EP4286004A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Disulfide oligosaccharide compounds and complexes
|
EP4286394A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
EP4169578A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
EP4285933A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide complexes and uses
|
EP4169580A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
WO2023067123A1
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Oligosaccharide complexes and uses
|
WO2023067124A1
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Disulfide oligosaccharide compounds and complexes
|
EP4169534A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Oligosaccharide complexes and uses
|
WO2023067126A1
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
WO2023094713A2
(en)
|
2021-11-29 |
2023-06-01 |
BioNTech SE |
Coronavirus vaccine
|
WO2023105005A1
(en)
|
2021-12-09 |
2023-06-15 |
BioNTech SE |
Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
|
WO2024046572A1
(en)
|
2022-09-01 |
2024-03-07 |
BioNTech SE |
Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
|
WO2023116804A1
(zh)
|
2021-12-23 |
2023-06-29 |
苏州艾博生物科技有限公司 |
脂质化合物和脂质纳米颗粒组合物
|
WO2023138786A1
(en)
|
2022-01-21 |
2023-07-27 |
BioNTech SE |
Analysis of rna molecules using catalytic nucleic acids
|
WO2023144330A1
(en)
|
2022-01-28 |
2023-08-03 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
WO2023147091A1
(en)
|
2022-01-28 |
2023-08-03 |
BioNTech SE |
Coronavirus vaccine
|
WO2023166425A1
(en)
|
2022-03-01 |
2023-09-07 |
Crispr Therapeutics Ag |
Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
|
WO2023180904A1
(en)
|
2022-03-21 |
2023-09-28 |
Crispr Therapeutics Ag |
Methods and compositions for treating lipoprotein-related diseases
|
WO2023213378A1
(en)
|
2022-05-02 |
2023-11-09 |
BioNTech SE |
Replicon compositions and methods of using same for the treatment of diseases
|
WO2023227608A1
(en)
|
2022-05-25 |
2023-11-30 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
WO2023232747A1
(en)
|
2022-05-30 |
2023-12-07 |
BioNTech SE |
Complexes for delivery of nucleic acids
|
WO2023237726A1
(en)
|
2022-06-10 |
2023-12-14 |
Pantarhei Oncology B.V. |
An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer
|
WO2024002985A1
(en)
|
2022-06-26 |
2024-01-04 |
BioNTech SE |
Coronavirus vaccine
|
WO2024017479A1
(en)
|
2022-07-21 |
2024-01-25 |
BioNTech SE |
Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
|
WO2024037578A1
(en)
|
2022-08-18 |
2024-02-22 |
Suzhou Abogen Biosciences Co., Ltd. |
Composition of lipid nanoparticles
|
WO2024056856A1
(en)
|
2022-09-15 |
2024-03-21 |
BioNTech SE |
Systems and compositions comprising trans-amplifying rna vectors with mirna
|
WO2024068545A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
WO2024068674A1
(en)
|
2022-09-26 |
2024-04-04 |
BioNTech SE |
Nucleic acid complexes and uses thereof
|
WO2024086575A1
(en)
|
2022-10-17 |
2024-04-25 |
BioNTech SE |
Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection
|
WO2024084462A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Nucleic acid complexes and uses thereof
|
WO2024089638A1
(en)
|
2022-10-28 |
2024-05-02 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine
|
WO2024097639A1
(en)
|
2022-10-31 |
2024-05-10 |
Modernatx, Inc. |
Hsa-binding antibodies and binding proteins and uses thereof
|
WO2024107754A1
(en)
|
2022-11-15 |
2024-05-23 |
Genentech, Inc. |
Selection of diverse candidate peptides for peptide therapeutics
|
WO2024118866A1
(en)
|
2022-12-01 |
2024-06-06 |
Modernatx, Inc. |
Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|